Linzoglad Dry Syrup is a pediatric formulation containing linezolid, a synthetic antibiotic effective against a range of Gram-positive bacterial infections. It is designed for ease of administration to children, offering a palatable option for those who may have difficulty swallowing tablets. Linezolid works by inhibiting bacterial protein synthesis, making it particularly useful in treating infections caused by resistant organisms, such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE).

This syrup is indicated for the treatment of various serious infections, including pneumonia, skin and soft tissue infections, and certain types of bacteremia. Its formulation ensures accurate dosing, which is critical in pediatric care. As an oxazolidinone antibiotic, Linzoglad targets the bacterial ribosome, disrupting the production of essential proteins and ultimately leading to bacterial cell death.

Linzoglad is recommended for use under the supervision of a healthcare professional, and its safety profile has been established in clinical trials. Parents and caregivers should closely monitor the child for any adverse reactions and maintain communication with their healthcare provider throughout the treatment course.

About the Product

Common side effects may include nausea, diarrhea, headache, and allergic reactions. Serious side effects, such as serotonin syndrome or peripheral neuropathy, should be reported immediately.

Linzoglad Dry Syrup is indicated for the treatment of serious infections caused by susceptible Gram-positive bacteria, including MRSA and VRE.

Use Linzoglad only under medical supervision, and complete the full course of treatment to prevent the development of antibiotic resistance.